THREAD and Trialbee Partner in Global DCT Inclusivity and Recruitment
THREAD has announced a partnership with patient matching and enrollment platform Trialbee to streamline patient recruitment for sponsors and contract research organizations (CROs) on a global scale. The partnership combines THREAD’s DCT technology solution for remotely capturing data from trial participants with Trialbee’s platform for patient matching and enrollment in clinical trials, including those with rare conditions.
Participants are targeted for outreach based on a real-world, data-driven model. After completing the online prequalification process, participants receive virtual or phone-based nurse qualification interviews through a clinical call center before the information is sent to THREAD’s platform, where site staff make final assessments.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
